108 related articles for article (PubMed ID: 26936307)
21. Waist circumference and a body shape index and prostate cancer risk and mortality.
Jochems SHJ; Wood AM; Häggström C; Orho-Melander M; Stattin P; Stocks T
Cancer Med; 2021 Apr; 10(8):2885-2896. PubMed ID: 33710775
[TBL] [Abstract][Full Text] [Related]
22. Role of abdominal obesity for functional outcomes and complications in men treated with radical prostatectomy for prostate cancer: results of the Multicenter Italian Report on Radical Prostatectomy (MIRROR) study.
Gacci M; Sebastianelli A; Salvi M; De Nunzio C; Schiavina R; Simonato A; Tubaro A; Mirone V; Carini M; Carmignani G
Scand J Urol; 2014 Apr; 48(2):138-45. PubMed ID: 23781856
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States.
Wong ND; Lopez V; Tang S; Williams GR
Am J Cardiol; 2006 Jul; 98(2):204-8. PubMed ID: 16828593
[TBL] [Abstract][Full Text] [Related]
24. The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Shetti MB; Merrick GS; Butler WM; Galbreath R; Torlone A; Lief JH; Adamovich E; Wallner KE
Am J Clin Oncol; 2012 Dec; 35(6):572-9. PubMed ID: 22134514
[TBL] [Abstract][Full Text] [Related]
25. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study.
Han TS; Williams K; Sattar N; Hunt KJ; Lean ME; Haffner SM
Obes Res; 2002 Sep; 10(9):923-31. PubMed ID: 12226141
[TBL] [Abstract][Full Text] [Related]
26. Effects of components of metabolic syndrome on sexual function in Korean BPH/LUTS patients.
Lee SH; Kim JC; Lee JY; Kim JH; Oh CY; Lee SW; Yoo SJ; Chung BH
J Sex Med; 2009 Aug; 6(8):2292-8. PubMed ID: 19493291
[TBL] [Abstract][Full Text] [Related]
27. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
28. Impact of the metabolic syndrome and its components combinations on arterial stiffness in Type 2 diabetic men.
Levisianou D; Melidonis A; Adamopoulou E; Skopelitis E; Koutsovasilis A; Protopsaltis I; Zairis M; Kougialis S; Skoularigis I; Koukoulis G; Foussas S; Triposkiadis F
Int Angiol; 2009 Dec; 28(6):490-5. PubMed ID: 20087288
[TBL] [Abstract][Full Text] [Related]
29. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
30. The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer.
Bar D; Lavie O; Stein N; Feferkorn I; Shai A
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():227-231. PubMed ID: 27890326
[TBL] [Abstract][Full Text] [Related]
31. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
32. The metabolic syndrome and risk of prostate cancer in Italy.
Pelucchi C; Serraino D; Negri E; Montella M; Dellanoce C; Talamini R; La Vecchia C
Ann Epidemiol; 2011 Nov; 21(11):835-41. PubMed ID: 21982487
[TBL] [Abstract][Full Text] [Related]
33. Type 2 diabetes and the risk of mortality among patients with prostate cancer.
Bensimon L; Yin H; Suissa S; Pollak MN; Azoulay L
Cancer Causes Control; 2014 Mar; 25(3):329-38. PubMed ID: 24384808
[TBL] [Abstract][Full Text] [Related]
34. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
[TBL] [Abstract][Full Text] [Related]
35. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study.
Stürmer T; Buring JE; Lee IM; Gaziano JM; Glynn RJ
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2391-7. PubMed ID: 17164361
[TBL] [Abstract][Full Text] [Related]
36. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
[TBL] [Abstract][Full Text] [Related]
37. Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
Bosco C; Wong C; Garmo H; Crawley D; Holmberg L; Hammar N; Adolfsson J; Stattin P; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):260-267. PubMed ID: 28940667
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis.
Rosato V; Tavani A; Bosetti C; Pelucchi C; Talamini R; Polesel J; Serraino D; Negri E; La Vecchia C
Metabolism; 2011 Oct; 60(10):1372-8. PubMed ID: 21550085
[TBL] [Abstract][Full Text] [Related]
39. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
[TBL] [Abstract][Full Text] [Related]
40. A cohort study of digoxin exposure and mortality in men with prostate cancer.
Flahavan EM; Sharp L; Bennett K; Barron TI
BJU Int; 2014 Feb; 113(2):236-45. PubMed ID: 23937513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
